Cyramza：大腸癌治療薬市場分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Clinical Staging 15
3.3 Symptoms 16
4 Disease Management 18
4.1 Diagnosis and Treatment Overview 18
4.1.1 Screening and Diagnosis 18
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 21
4.1.3 Clinical Practice 25
5 Competitive Assessment 32
5.1 Overview 32
6 Unmet Need and Opportunity 34
6.1 Overview 34
6.2 Therapies That Provide Substantial Overall Survival Benefit for Metastatic Patients 35
6.2.1 Unmet Need 35
6.2.2 Gap Analysis 37
6.2.3 Opportunity 37
6.3 Targeted Treatments for KRAS and BRAF Mutaton-Positive Patients 39
6.3.1 Unmet Need 39
6.3.2 Gap Analysis 40
6.3.3 Opportunity 40
6.4 Effective Neoadjuvant/Adjuvant Therapies for High Risk Resectable Disease 41
6.4.1 Unmet Need 41
6.4.2 Gap Analysis 42
6.4.3 Opportunity 42
6.5 Tolerable Later-Line Therapies For Chemotherapy-Resistant Patients 43
6.5.1 Unmet Need 43
6.5.2 Gap Analysis 43
6.5.3 Opportunity 44
7 Pipeline Assessment 45
7.1 Overview 45
7.2 Promising Drugs in Clinical Development 46
8 Cyramza (Ramucirumab) 48
8.1 Overview 48
8.2 Efficacy 51
8.3 Safety 51
8.4 Dosing and Formulation 51
8.5 Potential Clinical and Commercial Positioning 52
8.6 SWOT Analysis 53
8.7 Forecast 54
9 Appendix 55
9.1 Bibliography 55
9.2 Abbreviations 60
9.3 Methodology 64
9.4 Forecasting Methodology 64
9.4.1 Diagnosed Colorectal Cancer Patients 64
9.4.2 Percent Drug-Treated Patients 65
9.4.3 General Pricing Assumptions 65
9.4.4 Average Body Weight and Surface Area Across the 8MM 66
9.4.5 Generic Erosion 66
9.4.6 Pricing of Pipeline Agents 66
9.5 Primary Research – KOLs Interviewed for this Report 67
9.6 Primary Research – Prescriber Survey 68
9.7 About the Authors 69
9.7.1 Analyst 69
9.7.2 Global Head of Healthcare 70
9.8 About GlobalData 71
9.9 Disclaimer 71